XZ 700
Alternative Names: Staphefekt™XZ.700; XZ-700; XZ.700Latest Information Update: 28 Apr 2022
At a glance
- Originator Micreos
- Class Antibacterials; Endolysins; Peptides; Skin disorder therapies
- Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Atopic dermatitis
- Research Cutaneous T-cell lymphoma; Wound infections
- No development reported Staphylococcal infections
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for clinical-Phase-Unknown development in Staphylococcal-infections in Netherlands
- 14 Apr 2022 Pharmacodynamics data of XZ 700 in Staphylococcal infections released by Micreos
- 14 Oct 2021 Early research in Cutaneous T-cell lymphoma in Netherlands, prior to October 2021 (unspecified route)